Olema Pharmaceuticals, Inc. OLMA 深 滬
等待開盤 08-21 09:30:00 美东时间
10.80
-0.510
-4.51%
華盛通- 最 高11.11
- 今 開11.10
- 成交量 56.00万股
- 最 低 10.67
- 昨 收 11.31
- 總市值 9.45亿
- 52周最高 36.2591
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 5.36
- 委 比 59.35%
- 總股本 8749.76万
- 歷史最高 60.27
- 量 比 0.68
- 振 幅 3.89%
- 歷史最低 2.00
- 每 手 1
- 風險率 7.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Olema Oncology names Jason O’Byrne as CFO
Olema Pharmaceuticals (OLMA) has appointed Jason O’Byrne as chief financial officer. O’Byrne brings more than two decades of finance and global operations leadership across high-growth biotechnology a...
08-13 21:25
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Olema Pharmaceuticals, Inc. ("Olema Oncology") announced the appointment of Jason O’Byrne, MBA, as Chief Financial Officer. O’Byrne brings over 20 years of finance and global operations leadership in biotech and pharma. He previously served as CFO at Vir Biotechnology and Caribou Biosciences, leading financial and capital markets initiatives, including IPOs and acquisitions. Olema Oncology is advancing therapies for breast cancer, with palazestra...
08-13 11:00
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.
08-12 03:28
OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of OppFi Inc (NYSE:OPFI) fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY26 guidance below estimates. OppFi ...
08-11 20:04
财报速睇 | Olema Pharmaceuticals 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.63亿美元，同比亏损扩大44.3%
华盛资讯8月11日讯，Olema Pharmaceuticals公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.63亿美元，同比亏损扩大44.3%。
08-11 06:25
Olema Pharmaceuticals Q2 EPS $(0.61) Misses $(0.55) Estimate
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.55) by 10.91 percent. This is a 19.61 percent decrease over losses of $(0.51) per share from the same period last year.
08-11 04:29
财报速睇 | Olema Pharmaceuticals 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.63亿美元，同比亏损扩大43.2%
华盛资讯8月11日讯，Olema Pharmaceuticals公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.63亿美元，同比亏损扩大43.2%。
08-11 04:17
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Pharmaceuticals reported Q2 2026 results, highlighting completion of enrollment in the pivotal Phase 3 OPERA-01 trial for palazestrant, with top-line data expected in Q1 2027. Initial Phase 1 data for OP-3136, a KAT6 inhibitor, were presented at ASCO 2026, showing promising anti-tumor activity. The company also announced a collaboration with Bayer to evaluate OP-3136 in combination with darolutamide for metastatic castration-resistant prost...
08-10 20:01
Olema Pharmaceuticals Reports Initial Clinical Data From The Phase 1 Study of OP-3136, A KAT6 Inhibitor, At 2026 ASCO Annual Meeting; OP-3136 Monotherapy Was Well-tolerated With No Dose-limiting Toxicities Observed And No Discontinuations Due To Treatment-related Adverse Events; OP-3136 Shows Evidence Of Anti-tumor Activity Across Multiple Solid Tumor Types
Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and
05-22 05:08
